News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference
JPMorgan Healthcare Conference 2013
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer View HTML
Toggle Summary American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension View HTML
Toggle Summary Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
Financing Underscores Strong Clinical Progress and Positive Data in Lead Program
View HTML
Toggle Summary Biocentury - RhoKing Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue
View HTML